Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis

SARIKAYA, Savaş; Sarp, Ümit; Turan, Yasar; DEMİR, Vahit; Uçar, Mehmet; BÖREKCİ, ELİF; Erbay, Ali Rıza; AKYOL, Lütfi

Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis

Mehmet UÇAR, (Bozok Üniversitesi, Tıp Fakültesi, Fiziksel Tıp ve Tedavi Rehabilitasyon, Bölümü, Yozgat, Türkiye)

Savaş SARIKAYA, (Bozok Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Yozgat, Türkiye)

Ümit SARP, (Yozgat Devlet Hastanesi, Fiziksel Tedavi ve Rehabilitasyon Kliniği, Yozgat, Türkiye)

Yaşar TURAN, (Bozok Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Yozgat, Türkiye)

Lütfi AKYOL, (Bozok Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Yozgat, Türkiye)

ELİF BÖREKCİ, (Bozok Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Yozgat, Türkiye)

Ali Rıza ERBAY, (Bozok Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Yozgat, Türkiye)

Vahit DEMİR (Yozgat Devlet Hastanesi, Kardiyoloji Kliniği, Yozgat, Türkiye)

Archives of Rheumatology

1 1

Yıl: 2015 Cilt: 30 Sayı: 3 Sayfa Aralığı: 221 - 225 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis

Öz:

Objectives: This study aims to evaluate cardiometabolic risk factors in ankylosing spondylitis (AS) patients and their relationship with epicardial fat thickness (EFT). Patients and methods: The study included 50 consecutive AS patients (29 males, 21 females; mean age 40.5±9.4 years; range 25 to 60 years) with a median disease duration of 8.3 years and 50 healthy controls (33 males, 17 females; mean age 39.8±6.4 years, range 24 to 58 years). All patients EFT was measured with echocardiography. Results: Both body mass index and waist circumference measurements were higher in AS patients than healthy controls (25.4±3.5. vs. 24.5±2.9 kg/m2 , p=0.005; 96.2±10.8 vs. 86.7±12.6 cm, p<0.001; respectively). Triglyceride levels were higher in AS patients than healthy controls (123.0±47.7 vs. 110.1±61.0 mg/dL, p=0.009; respectively). High-density lipoprotein cholesterol levels were lower in AS patients than healthy controls (41.3±7.0 vs. 51.9±7.0 mg/dL, p<0.001; respectively). The EFT of AS patients was greater (0.53±0.14 vs. 0.45±0.02 cm, p<0.001; respectively) and was positively correlated with age (r=0.420, p=0.002), disease duration (r=0.609, p<0.001), body mass index (r=0.419, p=0.002), waist circumference (r=0.469, p<0.001), and triglyceride (r=0.434, p=0.002) levels; and negatively correlated with high-density lipoprotein cholesterol levels (r= -0.662, p<0.001). Conclusion: As a cardiometabolic risk factor, EFT was greater in AS patients. EFT is a noninvasive method to evaluate cardiometabolic risk factors in AS patients

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Genre F, López-Mejías R, Rueda-Gotor J, MirandaFilloy JA, Ubilla B, Carnero-López B, et al. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect. Mediators Inflamm 2014;2014:798060.
2. van der Horst-Bruinsma IE, Nurmohamed MT, Landewé RB. Comorbidities in patients with spondyloarthritis. Rheum Dis Clin North Am 2012;38:523-38.
3. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6.
4. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009;88:358-65.
5. Mathieu S, Motreff P, Soubrier M. Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 2010;77:542-5.
6. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-43.
7. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003;88:5163-8.
8. Malavazos AE, Ermetici F, Cereda E, Coman C, Locati M, Morricone L, et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis 2008;18:523-30.
9. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab 2006;91:4620-7.
10. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011;22:450-7.
11. Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM. Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 2011;146:452-4.
12. Nilgun U, Kurt M, Atcı N, Ya¤ız E, Güler H, Turhano¤lu A. Increased Epicardial Fat Tissue is a Marker of Subclinic Atherosclerosis. Arch Rheumatol 2014;29:1-6.b
13.Resorlu H, Akbal A, Resorlu M, Gokmen F, Ates C, Uysal F, et al. Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clin Rheumatol 2015;34:295-9.
14. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
15.Söker G, Gülek B, Tufan MA, Söker E, Kelle B, Öztürk AB. Early diagnosis of hip joint involvement of ankylosing spondylitis using magnetic resonance imaging in the absence of clinical and x-ray findings. Arch Rheumatol 2014;29:99-104.
16. Yildirir A, Aksoyek S, Calguneri M, Aytemir K, Apras S, Kiraz S, et al. No evidence of cardiac autonomic involvement in ankylosing spondylitis, as assessed by heart rate variability. Clin Rheumatol 2001;20:185-8.
17. Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol 2006;25:24-9.
18. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
19. Ben-Zvi I, Goldenberg I, Matetzky S, Grossman C, Elis A, Gavrielov-Yusim N, et al. The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome. Clin Rheumatol 2014. [Epub ahead of print].
20.Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 2003;11:304-10.
21. Iacobellis G, Willens HJ, Barbaro G, Sharma AM. Threshold values of high-risk echocardiographic epicardial fat thickness.Obesity (Silver Spring) 2008;16:887-92.
22.Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008;40:442-5.
23.Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J 2007;153:907-17. 24.Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 2008;10:207.
25.Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007;26:710-4.
26.Flüchter S, Haghi D, Dinter D, Heberlein W, Kühl HP, Neff W, et al. Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. Obesity (Silver Spring) 2007;15:870-8.
27. Wang TD, Lee WJ, Shih FY, Huang CH, Chang YC, Chen WJ, et al. Relations of epicardial adipose tissue measured by multidetector computed tomography to components of the metabolic syndrome are regionspecific and independent of anthropometric indexes and intraabdominal visceral fat. J Clin Endocrinol Metab 2009;94:662-9.
28.Silaghi A, Piercecchi-Marti MD, Grino M, Leonetti G, Alessi MC, Clement K, et al. Epicardial adipose tissue extent: relationship with age, body fat distribution, and coronaropathy. Obesity (Silver Spring) 2008;16:2424-30.
29.Ormseth MJ, Lipson A, Alexopoulos N, Hartlage GR, Oeser AM, Bian A, et al. Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013;65:1410-5.

APA	Uçar M, SARIKAYA S, Sarp Ü, Turan Y, AKYOL L, BÖREKCİ E, Erbay A, DEMİR V (2015). Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. , 221 - 225.
Chicago	Uçar Mehmet,SARIKAYA Savaş,Sarp Ümit,Turan Yasar,AKYOL Lütfi,BÖREKCİ ELİF,Erbay Ali Rıza,DEMİR Vahit Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. (2015): 221 - 225.
MLA	Uçar Mehmet,SARIKAYA Savaş,Sarp Ümit,Turan Yasar,AKYOL Lütfi,BÖREKCİ ELİF,Erbay Ali Rıza,DEMİR Vahit Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. , 2015, ss.221 - 225.
AMA	Uçar M,SARIKAYA S,Sarp Ü,Turan Y,AKYOL L,BÖREKCİ E,Erbay A,DEMİR V Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. . 2015; 221 - 225.
Vancouver	Uçar M,SARIKAYA S,Sarp Ü,Turan Y,AKYOL L,BÖREKCİ E,Erbay A,DEMİR V Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. . 2015; 221 - 225.
IEEE	Uçar M,SARIKAYA S,Sarp Ü,Turan Y,AKYOL L,BÖREKCİ E,Erbay A,DEMİR V "Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis." , ss.221 - 225, 2015.
ISNAD	Uçar, Mehmet vd. "Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis". (2015), 221-225.

APA	Uçar M, SARIKAYA S, Sarp Ü, Turan Y, AKYOL L, BÖREKCİ E, Erbay A, DEMİR V (2015). Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. Archives of Rheumatology, 30(3), 221 - 225.
Chicago	Uçar Mehmet,SARIKAYA Savaş,Sarp Ümit,Turan Yasar,AKYOL Lütfi,BÖREKCİ ELİF,Erbay Ali Rıza,DEMİR Vahit Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. Archives of Rheumatology 30, no.3 (2015): 221 - 225.
MLA	Uçar Mehmet,SARIKAYA Savaş,Sarp Ümit,Turan Yasar,AKYOL Lütfi,BÖREKCİ ELİF,Erbay Ali Rıza,DEMİR Vahit Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. Archives of Rheumatology, vol.30, no.3, 2015, ss.221 - 225.
AMA	Uçar M,SARIKAYA S,Sarp Ü,Turan Y,AKYOL L,BÖREKCİ E,Erbay A,DEMİR V Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. Archives of Rheumatology. 2015; 30(3): 221 - 225.
Vancouver	Uçar M,SARIKAYA S,Sarp Ü,Turan Y,AKYOL L,BÖREKCİ E,Erbay A,DEMİR V Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. Archives of Rheumatology. 2015; 30(3): 221 - 225.
IEEE	Uçar M,SARIKAYA S,Sarp Ü,Turan Y,AKYOL L,BÖREKCİ E,Erbay A,DEMİR V "Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis." Archives of Rheumatology, 30, ss.221 - 225, 2015.
ISNAD	Uçar, Mehmet vd. "Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis". Archives of Rheumatology 30/3 (2015), 221-225.